glp 1 gip combo The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology TrimRX | GLP-1 vs GIP:

Description

Although rates of adverse effects differ between specific agents, the most common adverse effects with the GLP-1 RA class are gastrointestinal (GI) related (nausea, vomiting, and diarrhea) and injection-site reactions

Rehab Abdelhamid: Writing review & editing, Validation, Investigation, Formal analysis, Conceptualization

Consensus estimates see the market for oral formulations stabilizing at about 30%. Limited head-to-head data comparing newer oral therapy to injections have shown similar safety and efficacy

Consumers across the income spectrum are making budgetary trade-offs and shopping differently this year, she said, adding, However, our data shows consumers continue to want to participate in snacking occasions. Third-quarter net sales declined 1.4% to $2.99 billion from $3.03 billion in the prior-year period